Mutations Accounting for Congenital Fibrinogen Disorders: An Update

Abstract

Fibrinogen is a complex protein that plays a key role in the blood clotting process. It is a hexamer composed of two copies of three distinct chains: Aα, Bβ, and γ encoded by three genes, FGA, FGB, and FGG, clustered on the long arm of chromosome 4. Congenital fibrinogen disorders (CFDs) are divided into qualitative deficiencies (dysfibrinogenemia, hypodysfibrinogenemia) in which the mutant fibrinogen molecule is present in the circulation and quantitative deficiencies (afibrinogenemia, hypofibrinogenemia) with no mutant molecule present in the bloodstream. Phenotypic manifestations are variable, patients may be asymptomatic, or suffer from bleeding or thrombosis. Causative mutations can occur in any of the three fibrinogen genes and can affect one or both alleles. Given the large number of studies reporting on novel causative mutations for CFDs since the review on the same topic published in 2016, we performed an extensive search of the literature and list here 120 additional mutations described in both quantitative and qualitative disorders. The visualization of causative single nucleotide variations placed on the coding sequences of FGA, FGB, and FGG reveals important structure function insight for several domains of the fibrinogen molecule.

Keywords

congenital fibrinogen disorders - mutations - afibrinogenemia - hypofibrinogenemia - dysfibrinogenemia - hypodysfibrinogenemia - bleeding - thrombosis

^* These authors contributed equally to this work.

Publikationsverlauf

Artikel online veröffentlicht:
24. Januar 2022

• References

• 1 Vilar R, Fish RJ, Casini A, Neerman-Arbez M. Fibrin(ogen) in human disease: both friend and foe. Haematologica 2020; 105 (02) 284-296
• 2 Weisel JW, Litvinov RI. Fibrin formation, structure and properties. Subcell Biochem 2017; 82: 405-456
• 3 Pieters M, Wolberg AS. Fibrinogen and fibrin: an illustrated review. Res Pract Thromb Haemost 2019; 3 (02) 161-172
• 4 Kant JA, Fornace Jr AJ, Saxe D, Simon MI, McBride OW, Crabtree GR. Evolution and organization of the fibrinogen locus on chromosome 4: gene duplication accompanied by transposition and inversion. Proc Natl Acad Sci U S A 1985; 82 (08) 2344-2348
• 5 de Maat MP, Verschuur M. Fibrinogen heterogeneity: inherited and noninherited. Curr Opin Hematol 2005; 12 (05) 377-383
• 6 Neerman-Arbez M, de Moerloose P, Casini A. Laboratory and genetic investigation of mutations accounting for congenital fibrinogen disorders. Semin Thromb Hemost 2016; 42 (04) 356-365
• 7 Casini A, de Moerloose P, Neerman-Arbez M. Clinical features and management of congenital fibrinogen deficiencies. Semin Thromb Hemost 2016; 42 (04) 366-374
• 8 Blombäck M, Blombäck B, Mammen EF, Prasad AS. Fibrinogen Detroit—a molecular defect in the N-terminal disulphide knot of human fibrinogen?. Nature 1968; 218 (5137): 134-137
• 9 Neerman-Arbez M, Honsberger A, Antonarakis SE, Morris MA. Deletion of the fibrinogen alpha-chain gene (FGA) causes congenital afibrinogenemia. J Clin Invest 1999; 103: 215-218
• 10 Casini A, Blondon M, Tintillier V. et al. Mutational epidemiology of congenital fibrinogen disorders. Thromb Haemost 2018; 118 (11) 1867-1874
• 11 Casini A, Brungs T, Lavenu-Bombled C, Vilar R, Neerman-Arbez M, de Moerloose P. Genetics, diagnosis and clinical features of congenital hypodysfibrinogenemia: a systematic literature review and report of a novel mutation. J Thromb Haemost 2017; 15 (05) 876-888
• 12 Hanss M, Biot F. A database for human fibrinogen variants. Ann N Y Acad Sci 2001; 936: 89-90
• 13 Vu D, Di Sanza C, Caille D. et al. Quality control of fibrinogen secretion in the molecular pathogenesis of congenital afibrinogenemia. Hum Mol Genet 2005; 14 (21) 3271-3280
• 14 Casini A, Vilar R, Beauverd Y. et al. Protein modelling to understand FGB mutations leading to congenital hypofibrinogenaemia. Haemophilia 2017; 23 (04) 583-589
• 15 Asselta R, Paraboschi EM, Duga S. Hereditary hypofibrinogenemia with hepatic storage. Int J Mol Sci 2020; 21 (21) 7830
• 16 Smith N, Bornikova L, Noetzli L. et al. Identification and characterization of novel mutations implicated in congenital fibrinogen disorders. Res Pract Thromb Haemost 2018; 2 (04) 800-811
• 17 Mukaddam A, Kulkarni B, Jadli A, Ghosh K, Shetty S. Spectrum of mutations in Indian patients with fibrinogen disorders and its application in genetic diagnosis of the affected families. Haemophilia 2015; 21 (06) e519-e523
• 18 Naz A, Biswas A, Khan TN. et al. Identification of novel mutations in congenital afibrinogenemia patients and molecular modeling of missense mutations in Pakistani population. Thromb J 2017; 15: 24
• 19 Aydin Köker S, Köker A, Neerman-Arbez M. et al. A novel frameshift mutation in the FGA gene (c.196 delT) leading to congenital afibrinogenemia. J Pediatr Hematol Oncol 2020; 42 (02) e98-e99
• 20 Amri Y, Toumi NelH, Hadj Fredj S, de Moerloose P. Congenital afibrinogenemia: identification and characterization of two novel homozygous fibrinogen Aα and Bβ chain mutations in two Tunisian families. Thromb Res 2016; 143: 11-16
• 21 Karimi M, Bordbar M, Aali M, Bazrafshan A, Tavoosi H, Gerdabi J. Successful delivery in an patient with afibrinogenemia after three abortions: a case report and review of the literature. Haemophilia 2018; 24 (02) e63-e66
• 22 Corrales-Medina FF, Miloh T, O'Farrell C, Andrews DM, Tekin A, De Angulo G. Liver transplantation as a novel strategy for resolution of congenital afibrinogenemia in a pediatric patient. J Thromb Haemost 2020; 18 (12) 3232-3235
• 23 Stanciakova L, Simurda T, Stasko J. et al. Novel fibrinogen bbeta chain mutation as an underlying mechanism of afibrinogenemia?. Semin Thromb Hemost 2015; 41 (08) 901-902
• 24 Zdziarska J, Wypasek E, Iwaniec T, Vilar R, Neerman-Arbez M, Undas A. Afibrinogenemia caused by a novel homozygous missense mutation, FGB p.Cys241Tyr, in a male patient with recurrent intracranial bleeding: case report and review of literature. Haemophilia 2021; 27 (01) 26-32
• 25 Grandone E, Tiscia G, Cappucci F. et al. Clinical histories and molecular characterization of two afibrinogenemic patients: insights into clinical management. Haemophilia 2012; 18 (01) e16-e18
• 26 Simurda T, Zolkova J, Snahnicanova Z. et al. Identification of two novel fibrinogen Bβ chain mutations in two Slovak families with quantitative fibrinogen disorders. Int J Mol Sci 2017; 19 (01) 19
• 27 Tavasoli B, Safa M, Dorgalaleh A. et al. Molecular and clinical profile of congenital fibrinogen disorders in Iran, identification of two novel mutations. Int J Lab Hematol 2020; 42 (05) 619-627
• 28 Malaquin S, Rebibo L, Chivot C, Badoux L, Mahjoub Y, Dupont H. Congenital afibrinogenemia: a case report of a spontaneous hepatic hematoma. Medicine (Baltimore) 2016; 95 (28) e4150
• 29 Rottenstreich A, Lask A, Schliamser L, Zivelin A, Seligsohn U, Kalish Y. Thromboembolic events in patients with severe inherited fibrinogen deficiency. J Thromb Thrombolysis 2016; 42 (02) 261-266
• 30 Virmond LA, Micheletti C, Pinto CMS. et al. Congenital afibrinogenemia in a patient with vascular abnormalities and a novel variant: clinical-molecular description and literature review. Blood Coagul Fibrinolysis 2020; 31 (01) 65-70
• 31 Chinni E, Tiscia G, Favuzzi G. et al. Identification of novel mutations in patients with fibrinogen disorders and genotype/phenotype correlations. Blood Transfus 2019; 17 (03) 247-254
• 32 Wang X, Tang N, Shen N, Lu Y, Li D. Congenital fibrinogen disorder caused by digenic mutations of the FGA and FGB genes. Hematology 2020; 25 (01) 145-148
• 33 Hanss M, Pouymayou C, Blouch MT. et al. The natural occurrence of human fibrinogen variants disrupting inter-chain disulfide bonds (AalphaCys36Gly, AalphaCys36Arg and AalphaCys45Tyr) confirms the role of N-terminal Aalpha disulfide bonds in protein assembly and secretion. Haematologica 2011; 96 (08) 1226-1230
• 34 Moret A, Zúñiga Á, Ibáñez M. et al. Clinical and molecular characterization by next generation sequencing of Spanish patients affected by congenital deficiencies of fibrinogen. Thromb Res 2019; 180: 115-117
• 35 Brennan SO, Brennan S, Laurie AD. Hypofibrinogenaemia associated with novel Aα126Val→Asp mutation in the fibrinogen coiled coil. Thromb Haemost 2017; 117 (10) 2000-2002
• 36 Vilar R, Casini A, Fournel A, Mourey G, Neerman-Arbez M. Identification and expression of a novel heterozygous frameshift mutation in FGA accounting for congenital hypofibrinogenemia in carriers of severe hemophilia A. Thromb Res 2020; 193: 5-8
• 37 Zhou P, Yu M, Peng Y, Ma P, Wan L. Identification and characterization of novel mutations in Chinese patients with congenital fibrinogen disorders. Blood Cells Mol Dis 2021; 86: 102489
• 38 Zhang H, Luo S, Fang W. et al. Phenotypic and genetic analysis of hypofibrinogenemia because of a novel missense mutation in the FGB: Leu121Arg. Blood Coagul Fibrinolysis 2019; 30 (05) 233-238
• 39 Taira C, Matsuda K, Arai S, Sugano M, Uehara T, Okumura N. A novel mutation in the fibrinogen Bβ Chain (c.490G>A; End of Exon 3) causes a splicing abnormality and ultimately leads to congenital hypofibrinogenemia. Int J Mol Sci 2017; 18 (11) 18
• 40 Kaido T, Yoda M, Kamijo T. et al. A novel amino acid substitution, fibrinogen Bβp.Pro234Leu, associated with hypofibrinogenemia causing impairment of fibrinogen assembly and secretion. Int J Mol Sci 2020; 21 (24) 21
• 41 Rakmanotham A, Ittiwut R, Komwilaisak P, Shotelersuk V, Sosothikul D, Suphapeetiporn K. A novel deletion in the fibrinogen beta chain (FGB) gene causing hypofibrinogenemia. Thromb Res 2020; 186: 26-29
• 42 Aung NN, Kennedy H, Faed JM, Brennan SO. Novel heterozygous Bbeta (c.1311T>A) mutation (Fibrinogen St Kilda) associated with recurrent pregnancy loss. Pathology 2015; 47 (06) 583-585
• 43 Simurda T, Vilar R, Zolkova J. et al. A novel nonsense mutation in FGB (c.1421G>A; p.Trp474Ter) in the beta chain of fibrinogen causing hypofibrinogenemia with bleeding phenotype. Biomedicines 2020; 8 (12) 8
• 44 Wypasek E, Klukowska A, Zdziarska J. et al. Genetic and clinical characterization of congenital fibrinogen disorders in Polish patients: identification of three novel fibrinogen gamma chain mutations. Thromb Res 2019; 182: 133-140
• 45 Zhou W, Luo M, Yan J. et al. A novel fibrinogen gamma-chain mutation, p.Cys165Arg, causes disruption of the γ165Cys-Bβ227Cys disulfide bond and ultimately leads to hypofibrinogenemia. Thromb Res 2018; 172: 128-134
• 46 Bauduer F, Mimoun A, Ménard F, de Mazancourt P. The fibrinogen FGG p.Gly242Glu: a rare mutation associated with hypofibrinogenemia. Blood Coagul Fibrinolysis 2018; 29 (04) 415-416
• 47 Brennan SO, Laurie AD, Raju N. Hypofibrinogenaemia with novel mutations (γ228Leu→Leu and γ229Gly→Glu) at neighbouring codons; allelic phase and expression level. Thromb Haemost 2016; 116 (02) 394-396
• 48 Simurda T, Caccia S, Asselta R. et al. Congenital hypofibrinogenemia associated with a novel heterozygous nonsense mutation in the globular C-terminal domain of the γ-chain (p.Glu275Stop). J Thromb Thrombolysis 2020; 50 (01) 233-236
• 49 Simurda T, Brunclikova M, Asselta R. et al. Genetic variants in the FGB and FGG genes mapping in the beta and gamma nodules of the fibrinogen molecule in congenital quantitative fibrinogen disorders associated with a thrombotic phenotype. Int J Mol Sci 2020; 21 (13) 21
• 50 Teraoka Y, Miyoshi H, Oshima K, Urabe S, Tanaka N, Kudo Y. Prenatal and peripartum management of patients with hypofibrinogenemia resulted in two successful deliveries. Case Rep Obstet Gynecol 2017; 2017: 9427359
• 51 Abdelghani E, Dawson J, Zajo K, Hallam M, Dunn A, Kumar R. Fibrinogen Columbus III: a novel c.963del frameshift mutation in the FGG gene resulting in hypofibrinogenemia with a bleeding phenotype. Pediatr Blood Cancer 2021; 68 (03) e28713
• 52 Callea F, Giovannoni I, Sari S. et al. A novel fibrinogen gamma chain mutation (c.1096C>G; p.His340Asp), fibrinogen Ankara, causing hypofibrinogenaemia and hepatic storage. Pathology 2017; 49 (05) 534-537
• 53 Nagata K, Arai S, Taira C, Sugano M, Honda T, Okumura N. A novel frameshift mutation in the fibrinogen γC terminal region, FGG c.1169_1170 del AT, leading to hypofibrinogenemia. Thromb Res 2017; 159: 82-85
• 54 Yan J, Luo M, Cheng P. et al. A novel mutation in the fibrinogen Aα chain (Gly13Arg, fibrinogen Nanning) causes congenital dysfibrinogenemia associated with defective peptide A release. Int J Hematol 2017; 105 (04) 506-514
• 55 Cao Z, Dong Y, Zeng J. et al. Whole-exome sequencing identified novel mutations in FGA and FGG genes in the patients with decreased fibrinogen. Thromb Res 2019; 177: 79-82
• 56 Zhou J, Ding Q, Wu W. et al. Dysfibrinogenemia-associated novel heterozygous mutation, Shanghai (FGA c.169_180+2 del), leads to N-terminal truncation of fibrinogen Aα chain and impairs fibrin polymerization. J Clin Pathol 2017; 70 (02) 145-153
• 57 Wang X, Li Y, Luo Z. et al. Fibrinogen BOE II: Intracerebral hemorrhage associated with a novel compound mutation in a Chinese family with dysfibrinogenemia. Thromb Res 2020; 196: 63-66
• 58 Brennan SO, Laurie AD, McRae S. Exon skipping and aberrant signal peptide cleavage produce novel fibrinogen with an Aα chain lacking the first 42 residues. Thromb Haemost 2016; 116 (03) 581-585
• 59 Salomon O, Barel O, Eyal E, Ganor RS, Kleinbaum Y, Shohat M. c.259A>C in the fibrinogen gene of alpha chain (FGA) is a fibrinogen with thrombotic phenotype. Appl Clin Genet 2019; 12: 27-33
• 60 Vasse M, Francois D, Van Dreden P, de Mazancourt P. Different sensitivity of von Clauss reagents for the diagnosis of dysfibrinogenemia. Eur J Haematol 2020; 104 (01) 70-71
• 61 Bouvier S, Chea M, Ripart S, Hanss M, de Mazancourt P, Gris J-C. Successful pregnancy under fibrinogen substitution with heparin and aspirin in a woman with dysfibrinogenemia revealed by placental abruption. Thromb Haemost 2018; 118 (11) 2006-2008
• 62 Shlebak AA, Katsarou AD, Adams G, Fernando F. A novel mutation in exon 2 of FGB caused by c.221G>T ^† substitution, predicting the replacement of the native Arginine at position 74 with a Leucine (p.Arg74Leu ^† ) in a proband from a Kurdish family with dysfibrinogenaemia and familial venous and arterial thrombosis. J Thromb Thrombolysis 2017; 43 (02) 263-270
• 63 Patil R, Mukaddam A, Ghosh K, Shetty S. Management of pregnancy in dysfibrinogenemia cases: a dilemma. Blood Coagul Fibrinolysis 2017; 28 (01) 91-93
• 64 Pietrys D, Balwierz W, Iwaniec T, Vorjohann S, Neerman-Arbez M, Undas A. Two different fibrinogen gene mutations associated with bleeding in the same family (A αGly13Glu and γGly16Ser) and their impact on fibrin clot properties: fibrinogen Krakow II and Krakow III. Thromb Haemost 2011; 106 (03) 558-560
• 65 Castaman G, Giacomelli SH, Biasoli C, Contino L, Radossi P. Risk of bleeding and thrombosis in inherited qualitative fibrinogen disorders. Eur J Haematol 2019; 103 (04) 379-384
• 66 Zhou J, Xin Y, Ding Q. et al. Thromboelastography predicts risks of obstetric complication occurrence in (hypo)dysfibrinogenemia patients under non-pregnant state. Clin Exp Pharmacol Physiol 2016; 43 (02) 149-156
• 67 Luo S, Xu Q, Xie Y. et al. A novel heterozygous mutation (γIIe367Thr) causes congenital dysfibrinogenemia in a Chinese family. Blood Coagul Fibrinolysis 2020; 31 (08) 569-574
• 68 Marchi R, Vilar R, Durual S. et al. Fibrin clot properties to assess the bleeding phenotype in unrelated patients with hypodysfibrinogenemia due to novel fibrinogen mutations. Thromb Res 2021; 197: 56-64
• 69 Asselta R, Robusto M, Platé M, Santoro C, Peyvandi F, Duga S. Molecular characterization of 7 patients affected by dys- or hypo-dysfibrinogenemia: identification of a novel mutation in the fibrinogen Bbeta chain causing a gain of glycosylation. Thromb Res 2015; 136 (01) 168-174
• 70 Brennan SO, Davis RL, Lowen R, Ruskova A. Deletion of five residues from the coiled coil of fibrinogen (Bbeta Asn167_Glu171del) associated with bleeding and hypodysfibrinogenemia. Haematologica 2009; 94 (04) 585-588
• 71 Yoda M, Kaido T, Taira C, Higuchi Y, Arai S, Okumura N. Congenital fibrinogen disorder with a compound heterozygote possessing two novel FGB mutations, one qualitative and the other quantitative. Thromb Res 2020; 196: 152-158
• 72 Amri Y, Kallel C, Becheur M. et al. Hypodysfibrinogenemia: a novel abnormal fibrinogen associated with bleeding and thrombotic complications. Clin Chim Acta 2016; 460: 55-62
• 73 Brennan SO, Chitlur M. Hypodysfibrinogenaemia and thrombosis in association with a new fibrinogen γ chain with two mutations (γ114Tyr→His, and γ320Asp deleted). Thromb Haemost 2013; 109 (06) 1180-1182
• 74 Ivaškevičius V, Thomas A, Biswas A. et al. A novel fibrinogen γ chain frameshift deletion (c.637delT) in a patient with hypodysfibrinogenemia associated with thrombosis. Hamostaseologie 2015; 35 (Suppl. 01) S27-S31
• 75 Kaido T, Yoda M, Kamijo T, Taira C, Higuchi Y, Okumura N. Heterozygous variant fibrinogen γA289V (Kanazawa III) was confirmed as hypodysfibrinogenemia by plasma and recombinant fibrinogens. Int J Lab Hematol 2020; 42 (02) 190-197
• 76 Zhu L, Zhao M, Wang M. et al. Congenital hypodysfibrinogenemia associated with a novel deletion of three residues (γAla289_Asp291del) in fibrinogen. J Thromb Thrombolysis 2018; 46 (02) 211-218
• 77 Brennan SO, Laurie A. Functionally compromised FGG variant (γ320Asp→Glu) expressed at low level in plasma fibrinogen. Thromb Res 2014; 134 (03) 744-746
• 78 Undas A, Zdziarska J, Iwaniec T. et al. Fibrinogen Krakow: a novel hypo/dysfibrinogenemia mutation in fibrinogen gamma chain (Asn325Ile) affecting fibrin clot structure and function. Thromb Haemost 2009; 101 (05) 975-976
• 79 Ushijima A, Komai T, Masukawa A. et al. Hypodysfibrinogenemia with a heterozygous mutation of γCys326Ser by the novel transversion of TGT to TCT in a patient with pulmonary thromboembolism and right ventricular thrombus. Cardiology 2017; 137 (03) 167-172
• 80 Kumar R, Dawson J, Varga E, Canini JT, Monda KL, Dunn AL. Fibrinogen Columbus II: A novel c.1075G>T mutation in the FGG gene causing hypodysfibrinogenemia and thrombosis in an adolescent male. Pediatr Blood Cancer 2019; 66 (09) e27832
• 81 Peng Y, Nie L, Qin C, Wan L, Zhou P. Combined congenital hypodysfibrinogemia and factor XI deficiency in a Chinese family. Acta Haematol 2020; 143 (05) 472-477
• 82 Mukai S, Nagata K, Ikeda M. et al. Genetic analyses of novel compound heterozygous hypodysfibrinogenemia, Tsukuba I: FGG c.1129+62_65 del AATA and FGG c.1299+4 del A. Thromb Res 2016; 148: 111-117
• 83 Brennan SO, Oliver J, Davis RL. Adjacent substitutions (γ352Gly→Cys and 353Thr→Pro) in fibrinogen Ilam cause diminished γ chain expression. Thromb Haemost 2011; 105 (02) 379-381